HIV-1 protease inhibitors

Clinical Infectious Diseases

Volumn 30, Issue SUPPL. 2, 2000, Pages

  Eron J J , Jr ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; VIRUS RNA;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; PRIORITY JOURNAL; VIRUS INHIBITION;

ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034456228     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313853     Document Type: Conference Paper

References (109)

1. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. HIV-protease inhibitors
4. Active human immunodeficiency virus protease is required for viral infectivity
5. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease
6. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
7. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
8. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor
9. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion
10. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
11. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
12. Viral dynamics in human immunodeficiency virus type 1 infection
13. HIV viral load markers in clinical practice
14. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection
15. 1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors
16. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy
17. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151
18. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
19. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
20. Safety and efficacy of ritonavir administered at two potentially maximum tolerated doses
21. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
22. Pharmacokinetics and tolerability studies of L-735,524, a new HIV protease inhibitor
23. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
24. Antiviral activity of L-735,524, an HIV protease inhibitor, in infected patients
25. 3
26. Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK 639) at escalating doses
27. A double-blind, randomized trial of indinavir (MK-639) alone or with zidovudine vs. zidovudine alone in zidovudine-naive patients
28. A phase II open-label, randomized study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (ddI) versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients
29. Treatment with a combination of indinavir, zidovudine and lamivudine in HIV-1-infected adults with prior antiretroviral use
30. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
31. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
32. Safety and activity of saquinavir in HIV infection
33. + T-cell counts in HIV-infected patients
34. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
35. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents
36. An overview of the preclinical development of the HIV protease inhibitor VX-478 (141W94)
37. 3
38. + cells per cubic millimeter
39. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
40. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200-500 CD4 cells per cubic millimeter
41. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
42. Report of the NIH panel to define principles of therapy of HIV infection
43. Guidelines for the use of antiretroviral therapy in HIV-infected adults and adolescents
44. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100 Week follow-up
45. Treatment with indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC): Three-year follow-up
46. An open-label, randomized, comparative study of d4T + 3TC + IDV versus ZDV + 3TC + IDV in treatment-naive HIV-infected patients (START 1)
47. An open-label, randomized, comparative study of d4T + ddI + 1DV versus ZDV + 3TC + 1DV in treatment-naive HIV-infected patients
48. A randomized, placebo-controlled trial of indinavir in combination with two nucleoside analogues in human immunodeficiency virus-infected persons with CD4 cell counts ≤200 per cubic millimeter
49. Predictors of virologic and clinical responses to indinavir (IDV)+ ZDV+ 3TC or ZDV + 3TC
50. Durable effect of VIRACEPT (nelfinavir mesylate, NFV) in triple combination therapy
51. Long-term comparison of BID and TID dosing Viracept (nelfinavir) in combination with stavudine (d4T) and lamivudine (3TC) in HIV patients
52. Activity of soft-gelatin capsule formulation of saquinavir in combination with two nucleosides in treatment-naive HIV-1-seropositive persons
53. Long-term evaluation of saquinavir-soft-gel-capsule or indinavir as part of combination triple therapy (CHEESE study)
54. TIDBID study: Fortovase (FTV) TID regimen compared to FTV BID or FTV + BID regiments in HIV-1-infected patients
55. Amprenavir (141W94, APV)/3TC/ZDV exerts durable antiviral acitivity in HIV-1-infected antiretroviral therapy naive subjects through 48 weeks of therapy
56. + counts greater than 400 cells/microliter and viral load greater than 5000 copies/mL
57. Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450
58. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
59. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir
60. Poor penetration of the male genital tract by HIV-1 protease inhibitors
61. Steady-state pharmacokinetic interactions between ritonavir (RTV), nelfinavir (NFV), and the nelfinavir active metabolite M8 (AG1402)
62. Phase II study of ritonavir-nelfinavir combination therapy: An update
63. Indinavir can be taken with regular meals when administered with ritonavir
64. Novel double protease combinations combining indinavir (IDV) with ritonavir (RTV): Results from first study
65. Co-administration of indinavir and nelfinavir: Pharmacokinetics, tolerability, antiviral activity, and preliminary viral resistance
66. Pharmacokinetics of an indinavir/ritonavir 800/100 mg BID regiment
67. Co-administration of indinavir and nelfinavir: Pharmocokinetics, tolerability, anti-viral activity, and preliminary resistance
68. Co-administration of indinavir (IDV) 1200 mg with nelfinavir (NFV) 1250 mg in a twice daily regiment: Preliminary safety, PK activity
69. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients
70. Study of protease inhibitor combination in Europe (SPICE): Saquinavir soft gelatin capsule (SQV-SGC) plus nelfinavir (NFV) in HIV-infected individuals
71. Preliminary assessment of 141W94 in combination with other protease inhibitors
72. Saquinavir/ritonavir may have better antiviral efficacy than either ritonavir or indinavir in HIV-infected antiretroviral naive patients
73. Durable clinical anti-HIV-1 activity (72 weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV) [DMP 266-003, cohort IV]
74. A phase II, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 24 weeks [DMP 266-006]
75. Initial effectiveness and tolerability of nelfinavir (NFV) in combination with efavirenz (EFV, SUSTIVA, DMP 266) in antiretroviral therapy naive or nucleoside analogue-experienced HIV-1-infected patients: Characterization in a phase II, open-label, multicenter study at 24 weeks [DMP 266-024]
76. A pilot study of indinavir, nevirapine, and 3TC in patients with advanced HIV disease
77. ACTG 364: Virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFV) in combination with new nucleoside analogues in nucleoside-experienced subjects
78. Retrospective analysis of protease inhibitor efficacy among patients failing a delavirdine regimen
79. Retained effectiveness of protease inhibitor (PI) therapy (Rx) following "protease sparing" nevirapine/nucleoside (NVP/nuc) combination therapy
80. Relationship of baseline genotype to RNA response in ACTG 333 after switching from long-term saquinavir (SQVhc) to indinavir (IDV) or saquinavir soft gelatin capsule (SQVsgc)
81. Prior saquinavir therapy leads to a modest decrease in subsequent responses to drug regimens containing indinavir or ritonavir
82. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
83. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
84. Combined quadruple therapy with ritonavir-saquinavir (RTV-SQV) + nucleosides in patients (p) who failed in triple therapy with RTV, SQV or indinavir (IDV)
85. Effects of a "salvage" combination therapy with ritonavir + saquinavir in HIV-infected patients previously treated with protease-inhibitors (PI)
86. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
87. Virologic responses to a ritonavirsaquinavir-containing regimen in patients who had previously failed nelfinavir
88. Genotypic and phenotypic characterization of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir
89. HIV-1 variants isolated from patients treated with the protease inhibitor nelfinavir are not cross-resistant to other protease inhibitors
90. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens
91. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
92. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
93. Ritonavir, saquinavir, and nevirapine as a salvage regiment for indinavir or ritonavir resistance
94. Molecular modeling and x-ray crystallographic studies of ritonavir, ABT-378, and their analogues bound to protease
95. Acitivity of ABT-378 against HIV protease-containing mutations conferring resistance to ritonavir
96. Virological evaluation of ritonavir-resistant HIV to the HIV protease inhibitor ABT-378
97. Increased bioavailability and plasma levels of the HIV-1 protease inhibitor ABT-378 in rats due to inhibition of the in vivo metabolism by ritonavir
98. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir
99. ABT-378/ritonavir (ABT-387/r) suppresses HIV RNA to <400 copies/mL in 95% of treatment-naive patients and in 78% of PI-experienced patients at 36 weeks
100. Multipledose, safety, tolerance, and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers
101. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor
102. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates
103. Resistance profile and drug combination studies of an HIV-1 protease inhibitor, BMS-232632
104. BMS-232632: Single and multiple oral dose safety and pharmacokinetic study in healthy volunteers
105. Antiviral activity and resistance profile of AG1776, a novel inhibitor of HIV-1 protease
106. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
107. Indinavir-associated lipodystrophy
108. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
109. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy